Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. The company has a nanotechnology drug suspension; and engages in the development and commercialization of dietary supplements. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company's products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat disease-causing infections, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. Clene Inc. is headquartered in Salt Lake City, Utah.
IPO Year:
Exchange: NASDAQ
Website: clene.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/4/2022 | Outperform → Perform | Oppenheimer | |
| 7/18/2022 | $16.00 | Buy | H.C. Wainwright |
| 5/2/2022 | $10.00 | Buy | Canaccord Genuity |
| 9/28/2021 | $20.00 | Outperform | Oppenheimer |
Fastest customizable press release news feed in the world
After successful completion of FDA Type C meeting, Clene expects to submit an NDA for CNM-Au8® under the accelerated approval pathway in the third quarter of 2026In January 2026, Clene completed an oversubscribed registered direct offering totaling over $28 million, including an initial tranche of more than $6 million and two additional tranches totaling over $22 million tied to regulatory milestones In May 2026, Clene amended its existing $10 million convertible debt facility, extending maturity by six months to August 2027 and eliminating required monthly principal and interest payments before maturityIn May 2026, Clene completed a $7 million underwritten registered direct offering with a
MIAMI, May 06, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 92nd Emerging Growth Conference on May 6 & 7, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter. Presenting today – Wednesday, May 6, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene" or the "Company") and its wholly owned subsidiary, Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced the pricing of an underwritten registered direct offering of 1,000,000 shares of common stock at a purchase price of $7.00 per share to a single investor. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will participate in the following investor conferences in May. Emerging Growth ConferenceDate: May 6, 2026Time of Presentation: 3:25 p.m. ETFormat: Virtual PresentationPresentation Link: https://goto.webcasts.com/starthere.jsp?ei=1755070&tp_key=280dc3ffe3&sti=clnn D. Boral Capital Global Conference Date: M
MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on May 6 & 7, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - WednesdayMay 6, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to the re
FDA stated that the "proposed data may be capable of supporting the submission and review of an [NDA] under the accelerated approval pathway" for CNM-Au8 based on neurofilament light (NfL) biomarker dataFDA acknowledged NfL could potentially serve as a reasonably likely surrogate endpointClene expects to submit an NDA for CNM-Au8 to the FDA in the third quarter of 2026CNM-Au8 represents a potential first-in-class therapeutic approach for ALS, a disease area with significant unmet medical need SALT LAKE CITY, May 04, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopha
In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8® data submitted; Clene expects formal written meeting minutes early in the second quarter 2026Oversubscribed registered direct offering of over $28 million priced above market Initial financing tranche of over $6 million, which will provide cash runway to the end of the third quarter enabling funding through potential NDA acceptance decision by the FDACompletion of this financing through its three tranches is expected to provide the Company with sufficient capital into 2027 SALT LAKE CITY, March 12, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Cl
MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 90th Emerging Growth Conference on February 25 & 26, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - February 25, 2026 – Agenda for Today: 8:45Virtual Lobby opens.Register for the Conference. If you already regi
Operating capital runway sufficient into the fourth quarter of 2026 In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8 data submitted in late 2025Anticipated submission of a New Drug Application (NDA) to FDA for CNM-Au8 via an accelerated regulatory pathway in the second quarter of 2026Potential for FDA acceptance of this NDA and issuance of a Prescription Drug User Fee Act (PDUFA) date in the second half of 2026 SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene" or the "Company") and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical com
MIAMI, Feb. 24, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 90th Emerging Growth Conference on February 25 & 26, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - WednesdayFebruary 25, 2026 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Oppenheimer downgraded Clene from Outperform to Perform
H.C. Wainwright initiated coverage of Clene with a rating of Buy and set a new price target of $16.00
Canaccord Genuity initiated coverage of Clene with a rating of Buy and set a new price target of $10.00
Oppenheimer initiated coverage of Clene with a rating of Outperform and set a new price target of $20.00
Maxim Group initiated coverage of Clene with a rating of Buy and set a new price target of $18.00
Cantor Fitzgerald initiated coverage of Clene with a rating of Overweight and set a new price target of $22.00
Benchmark initiated coverage of Clene with a rating of Buy and set a new price target of $25.00
Benchmark initiated coverage of Clene with a rating of Buy and set a new price target of $25.00
Benchmark initiated coverage of Clene with a rating of Buy
Roth Capital initiated coverage of Clene with a rating of Buy and set a new price target of $24.00
SD - Clene Inc. (0001822791) (Filer)
8-K - Clene Inc. (0001822791) (Filer)
8-K - Clene Inc. (0001822791) (Filer)
10-Q - Clene Inc. (0001822791) (Filer)
8-K - Clene Inc. (0001822791) (Filer)
424B5 - Clene Inc. (0001822791) (Filer)
424B5 - Clene Inc. (0001822791) (Filer)
8-K - Clene Inc. (0001822791) (Filer)
DEFA14A - Clene Inc. (0001822791) (Filer)
DEF 14A - Clene Inc. (0001822791) (Filer)
Live Leadership Updates
SALT LAKE CITY, March 16, 2023 (GLOBE NEWSWIRE) -- Clene, Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the appointment of Benjamin Greenberg, M.D., M.H.S. as Head of Medical. An internationally recognized expert in treating disorders of the central nervous system, Dr. Greenberg brings extensive clinical and research experience to Clene as the company continues its development of CNM-Au8® as a potential treatment for amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). "Dr. Green
SALT LAKE CITY, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the appointment of Morgan Brown as Chief Financial Officer effective Feb. 1, 2022. "Morgan joins the executive team at a pivotal time in Clene's growth," stated Clene's President and CEO, Rob Etherington. "He is a seasoned healthcare executive and public-company biopharma CFO, who has led the out-licensing of commercial stage assets and M&A transactions as well as numerous substantial equity and
SALT LAKE CITY, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, today announced the appointment of Vallerie V. McLaughlin, MD, to its board as its seventh independent director. Dr. McLaughlin is the Kim A. Eagle MD Endowed Professor of Cardiovascular Medicine, Associate Chief Clinical Officer for Cardiovascular Services of the University of Michigan Medical Group, Associate Chief, Division of Cardiovascular Medicine, and Director of the Pulm
SALT LAKE CITY, May 19, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using bioenergetic nanocatalysis, today announced the appointment of David J. Matlin as Chairman of the Board. He has served as a Director of Clene since 2020. Mr. Matlin is the Chief Executive Officer of MatlinPatterson Global Advisers, a global private equity firm he co-founded in 2002. Previously, he was a Managing Director at Credit Suisse First Boston and a founding partner of Merrion Group. He currently serve
Live finance-specific insights
FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8's potential disease modifying activityCompany has requested a Type C meeting in the first quarter of 2026 to present the newly completed analyses supporting a planned NDA submission under the accelerated approval pathwayClene is hosting an investor webcast today at 8:30 am ET SALT LAKE CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene" or the "Company") and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinic
The primary endpoint of adjusted ALSFRS-R and secondary endpoints of CAFS and SVC were not met at 24 weeksPrespecified exploratory analyses of the secondary survival endpoint for the 30 mg dose demonstrated a >90% reduction in risk of death or risk of death/permanently assisted ventilation at 24 weeks Survival signal consistent with prior results from the Phase 2 RESCUE-ALS trialClene will continue the open-label extension of CNM-Au8 in the Healey ALS Platform Trial and is in discussions with the Healey & AMG ALS Center to design and offer an Expanded Access Protocol (EAP) of CNM-Au8 30mg for eligible participants of closed regimens and othersClene is pursuing multiple paths, including ongoi
SALT LAKE CITY, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will report topline results of the CNM-Au8® regimen of the HEALEY ALS Platform Trial on Monday, Oct. 3. Clene's management team will host a conference call and webcast to discuss the results. Conference Call and Webcast DetailsTime and Date: 8:30 a.m. EDT on Oct. 3, 2022Investors: 1 (888) 660-6179 (toll-free) or 1 (929) 203-1946 (toll)Conference ID: 5318408Webcast Link A live audio
CNM-Au8 met primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional Composite (mMSFC) compared to placebo over 48 weeks in the mITT populationConsistent improvements favoring CNM-Au8 were seen across paraclinical biomarkers, providing physiological evidence for its potential neuroprotective and remyelinating effectsCNM-Au8 treatment was well-tolerated, and there were no significant safety findings reportedResults provide support to advance CNM-Au8 into Phase 3 clinical developmentClene to host a call and webcast at 7:30 am EDT today SALT LAKE CITY, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiarie
SALT LAKE CITY, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will present results from its Phase 2 VISIONARY-MS trial at 7:30 a.m. EDT on Monday, August 15. Conference Call and Webcast Details:Presentation Time: 7:30 a.m. EDT on August 15, 2022 Investors (Toll free): 1 (888) 770-7152Conference ID: 5318408Webcast link A live audio webcast can also be accessed by visiting the Investors section of the Company's website presentations page. A replay o
RESCUE-ALS Phase 2 Trial did not meet primary MUNIX biomarker endpoint or secondary FVC endpoint at week 36; MUNIX efficacy signal was observed at week 12 (p=0.057)MUNIX trial results demonstrated protection of lower motor neurons in the pre-specified subset of limb onset ALS subjects (Wk12, p=0.0385; Wk36, p=0.0741), which represents approximately 70% of the ALS populationStatistically significant reductions in clinically relevant outcomes including ALS disease progression (p=0.0125), ALSFRS-R responder analysis (p=0.035), and improved ALS specific quality of life (p=0.018)Evidence for potential long-term survival benefit Results for Healey ALS Platform Trial Expected in the Second Half of
This live feed shows all institutional transactions in real time.
SC 13G/A - Clene Inc. (0001822791) (Subject)
SC 13G - Clene Inc. (0001822791) (Subject)
SC 13D/A - Clene Inc. (0001822791) (Subject)
SC 13G/A - Clene Inc. (0001822791) (Subject)
SC 13G/A - Clene Inc. (0001822791) (Subject)
SC 13G/A - Clene Inc. (0001822791) (Subject)
SC 13G - Clene Inc. (0001822791) (Subject)
SC 13G/A - Clene Inc. (0001822791) (Subject)
SC 13G - Clene Inc. (0001822791) (Subject)
SC 13G - Clene Inc. (0001822791) (Subject)